论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
4例儿童毛霉菌病的临床特点及预后
Received 18 March 2024
Accepted for publication 11 May 2024
Published 18 May 2024 Volume 2024:17 Pages 1971—1978
DOI https://doi.org/10.2147/IDR.S462725
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Héctor Mora-Montes
Li Li,1 Xiaoli Zhen,2 Wenjian Wang1
1Department of Respiratory Diseases, Shenzhen Children’s Hospital, Shenzhen, Guangdong, People’s Republic of China; 2Department of Radiology, Shenzhen Children’s Hospital, Shenzhen, People’s Republic of China
Correspondence: Wenjian Wang, Department of Respiratory Diseases, Shenzhen Children’s Hospital, No. 7019 Yitian Road, Futian District, Shenzhen, Guangdong, People’s Republic of China, Email wwjxx@126.com
Background: Mucormycosis is a fatal invasive fungal infection that commonly affects immunocompromised children. The aim of our study was to investigate the clinical manifestations, treatments, and prognosis of pediatric patients with mucormycosis.
Methods: We conducted a retrospective search in Shenzhen Children’s Hospital from July 2013 to July 2023 for all patients with mucormycosis. The clinical manifestation, pathogen detection, radiology, treatments, and prognosis were analyzed.
Results: Four cases were identified. Underlying conditions included acute myeloid leukemia with myeloid sarcoma (n = 1), thalassemia (post-allogeneic hematopoietic stem cell transplantation; n = 1), systemic lupus erythematosus (n = 1), and bilateral nephroblastoma (post-bilateral nephrectomy; n = 1). Two patients were disseminated mucormycosis, one case was pulmonary mucormycosis, and one case was cerebral mucormycosis. Fever, cough, and dyspnea were the main clinical symptoms of pulmonary mucormycosis, headache was the main clinical symptom of cerebral mucormycosis. Lung CT findings included consolidation, multiple nodules, halo sign, air crescent sign, and pleural effusion. The contrast-enhanced CT showed pulmonary artery and pulmonary vein occlusions in two patients and pseudoaneurysm in two patients. Amphotericin B formulations were administered as first-line therapy in all cases; in three cases, Triazole was administered in combination with amphotericin B.
Conclusion: Mucormycosis is a life-threatening disease involving multiple systems. Aorta pseudoaneurysm is a rare and fatal complication, enhanced CT can assist in diagnosis. Early diagnosis and appropriate therapeutic strategies are needed.
Keywords: children, immunocompromised, mucormycosis, pseudoaneurysm